They took advantage of the co-expression of two TAAs, carcino-embryonic antigen (CEA) and mesothelin (MSLN) on AsPC-1pancreatic cancer cells, to generate dCARs containing two physically separate CEA-CD3ζ and MSLN-4/1BB signaling domains controlled with CEA and MSLN, respectively. The gene discussed is MSLN; the disease is cancer.